CheckMate-459 presented efficacy data by PD-L1 expression and suggested that patients with expression at 1% or greater had a higher likelihood to present ORR to nivolumab: 28% vs 9% with sorafenib in patients with PD-L1 expression, compared with 12% vs 7% in patients without PD-L1 expression.13 Patients with HCC associated with viral hepatitis also were more sensitive to ICIs. This evidence concerns the gene CD274 and hepatocellular carcinoma.